Nonsteroidal antiinflammatory drugs and their effects: The importance of COX 'selectivity'

Journal of Clinical Rheumatology

Volumn 2, Issue 3, 1996, Pages 135-140

  Simon, Lee S ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Cyclooxygenase; Mechanism of action; Nonsteroidal antiinflammatory drugs; Prostaglandin synthase; Review

Indexed keywords

ETODOLAC; NAPROXEN; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; DRUG EFFECT; DRUG MECHANISM; DRUG SPECIFICITY; ENZYME INHIBITION; HUMAN; PRIORITY JOURNAL;

EID: 0029955717     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/00124743-199606000-00005     Document Type: Article

References (40)

1. Abramson SB, Weissman G. The mechanisms of action of nonsteroidal antiinflammatory drugs. Arthritis Rheum 1989;32:1-9.
2. Brooks PM, Day RO. Nonsteroidal antiinflammatory drugs: differences and similarities. N Engl J Med 1991;324:1716-1725.
3. Furst DE. Are there differences among non-steroidal antiinflammatory drugs? Comparing acetylated salicylates, nonacejylated salicylates, and nonacetylated nonsteroidal antiinflammatory drugs. Arthritis Rheum 1994;37:1-9.
4. Bombardier C, Peloso PMJ, Goldsmith CH, Salsalate-Diclofenac Study Group. Salsalate, a nonacetylated salicylate, is as efficacious as diclofenac in patients with rheumatoid arthritis. J Rheumatol 1995;22:617-624.
5. Multicenter Salsalte/Aspirin Comparison Trial Group. Does the acetyl group of aspirin contribute to the antiinflammatory efficacy of salicylic acid in the treatment of rheumatoid arthritis? J Rheumatol 1989;16:321-327.
6. Lu X, Xie W, Reed D. Nonsteroidal antiinflammatory drugs cause apoptosis and induce cyclooxygenases in chicken embryo fibroblasts. Proc Natl Acad Sci USA 1995;92:7961-7965.
7. Diaz-González F, González-Alvero I, Companero MR, et al. Prevention of in vitro neutrophil-endothelial attachment through shedding of L-selectin by nonsteroidal antiinflammatory drugs. J Clin Invest 1995;95:1756-1765.
8. Amin AR, Vyas P, Attur M. The mode of action of aspirin-like drugs: effect on inducible nitric oxide synthetase. Proc Natl Acad Sci USA 1995;92:7926-7930.
9. Hawkey CJ. Future treatments for arthritis: new NSAIDs, NO NSAIDs, or no NSAIDs? Gastroenterology 1995;109:614-616.
10. Meade EA, Smith WL, Dewitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isoenzymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1993;268:6610-6614.
11. DeWitt DL, Meade EA, Smith WL. PGH synthase isoenzyme selectivity: the potential for safer nonsteroidal antiinflammatory drugs. Am J Med 1993;93(Suppl 2A):40S-44S.
12. DeWitt DL, El-Harith EA, Kraemer SA, et al. The aspirin and heme-binding sites of ovine and murine prostaglandin endoperoxide synthases. J Biol Chem 1990;265:5192-5198.
13. Lee SH, Soyoola E, Chanmugam P, et al. Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. J Biol Chem 1992;267:25934-25938.
14. O'Banion MK, Winn VD, Young DA. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc Natl Acad Sci USA 1992;89:4888-4892.
15. Shimokawa T, Kulmacz RJ, Dewitt DL, Smith WL. Tyrosine 385 of prostaglandin endoperoxide synthase is required for cyclooxygenase catalysis. J Biol Chem 1990;265:20073-20076.
16. Shimokawa T, Smith WL. Essential histidines of prostaglandin endoperoxide synthase: His-309 is involved in heme-binding. J Biol Chem 1991;266:6168-6173.
17. Shimokawa T, Smith WL. Prostaglandin endoperoxide synthase: the aspirin acetylation region. J Biol Chem 1992;267:12387-12392.
18. Toh H. Prostaglandin endoperoxide synthase contains an EGF-like domain. FEBS Lett 1989; 258:317-319.
19. Glaser K, Sung M-L, O'Neill K, et al. Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1. Eur J Pharmacol 1995;281:107-111.
20. Hla T, Neilson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA 1992;89:7384-7388.
21. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1994;90:11693-11697.
22. Patrignani P, Panara MR, Greco A, et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther 1994;271:1705-1712.
23. Hayllar J, Bjarnason I. NSAIDs, Cox-2 inhibitors, and the gut. Lancet 1995;346:521-522.
24. Laine L, Sloane R, Ferretti M, Cominelli F. A randomized, double-blind comparison of placebo, etodolac, and naproxen on gastrointestinal injury and prostaglandin production. Gastrointest Endosc 1995;42:428-433.
25. Taha AS, McLaughlin S, Holland PJ, Kelly RW, Sturrock RD, Russell RJ. Effect on gastric and duodenal mucosal prostaglandins of repeated intake of therapeutic doses of naproxen and etodolac in rheumatoid arthritis. Ann Rheum Dis 1990;49:354-358.
26. Lanza F, Rack MF, Lynn M, Wolf J, Sanda M. An endoscopic comparison of the effects of etodolac, indomethacin, ibuprofen, naproxen, and placebo on the gastrointestinal mucosa. J Rheumatol 1987;14:338-341.
27. Roth SH, Tindall EA, Jain AK, et al. A controlled study comparing the effects of nabumetone, ibuprofen, and ibuprofen plus misoprostol on the upper gastrointestinal tract mucosa. Arch Intern Med 1993;153:2565-2571.
28. Cryer B, Goldschmiedt M, Redfern JS, Feldman M. Comparison of salsalate and aspirin on mucosal injury and gastroduodenal mucosal prostaglandins. Gastroenterology 1990; 99:1616-1621.
29. Schoen RT, Vender RJ. Mechanisms of non-steroidal antiinflammatory drug-induced gastric damage. Am J Med 1989, 86:449-458.
30. Soll AH, Weinstein WM, Kurata J, McCarthy D. Nonsteroidal anti-inflammatory drugs and peptic ulcer disease. Ann Int Med 1991;114: 307-319.
31. Allison MC, Howatson AG, Torance CJ. Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. N Engl J Med 1992;327:749-754.
32. Langenbach R, Morham SG, Tiano HF, et al. Prostaglandin synthase I gene disruption in mice reduces arachadonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 1995;83:483-492.
33. McCarthy DM. Nonsteroidal anti-inflammatory drugs: the clinical dilemmas. Scand J Gastroenterol 1992;27(Suppl)192:9-16.
34. Griffin MR, Piper JM, Daugherty JR, Snowdwn M, Ray WA. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Int Med 1991;114: 257-263.
35. Gabriel SE, Jaaklimainen L, Bombadier C. Risk for serious gastrointestinal complications related to use of nonsteroidal antiinflammatory drugs: a meta-analysis. Ann Int Med 1991;115: 787-796.
36. Fries JF, Williams CA, Bloch DA, Michel BA. Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med 1991;91:213-222.
37. Graham DY, White RH, Moreland LW, et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Ann Int Med 1993;119:257-262.
38. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. Ann Int Med 1995;123:214-249.
39. Raskin JB, White RH, Jackson JE, et al. Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparison of three regimens. Ann Intern Med 1995;123:344-350.
40. Larkai EN, Smith JL, Lidsky MD, Graham DY. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic non-steroidal anti-inflammatory drug use. Am J Gastroenterol 1987;82:1153-1158.